Our mission
AldexChem is a solution and platform provider for the Chemical and Life Science industries. Our mission is to support the development of new therapies that will improve the lives of millions worldwide.
SilBoRed™
AldexChem developed a novel hydrosilylation reaction filing its primary IP as SilBoRed™. A technology to reduce esters to aldehydes which are difficult, if not impossible with the standard chemistry toolbox. SilBoRed™ technology opened up a novel chemical space, leading to several industrial applications.
We are dedicated to provide robust and scalable tools for the chemical industries and we develop building blocks for a wide range of applications.
LipexSil™
One of these applications is creating novel ionizable cationic lipid families, which belong to the trademark LipexSil™ and filing AldexChem's secondary IP. LipexSil™ lipid families are a solution to one of the most pressing challenges of the pharma industry – the delivery of biologically active agents.
LipexSil™ novel ionizable lipids can be used in the preparation of LNPs to facilitate the therapeutic oligonucleotides into cells.
Our vision
We strive to solve challenges faced by the pharma industry, such as efficient delivery of biologically active agents with the help of our SilBoRed™ and LipexSil™ technologies. Our vision is to inspire change in the scientific community by pushing the boundaries of chemical synthesis. We think that by empowering the Chemical and Life Science sector with innovative and impactful solutions, we can contribute to a brighter future for all.
Present
lipids are successfully completed.
Reaction scope investigation, and technological development of SilBoRed™ borane
catalysts’ applications are launched.
SilBoRed™ is registered as a Hungarian national trademark (SZTNH), and
applications for international trademarks (WIPO) have been started.
generation lipids in the transfection of GFP and Luciferase mRNA into cells with
accompanying low toxicity. Based on these successful transfection screening,investigation of further selected lipids is initiated to determine the transfection and
toxicity in the function of mRNA concentration.
completed. 5 best performer lipids are selected for in vivo studies on mice
(immunogenicity, transfection and toxicity studies).
Preliminary in vitro biological results of the selected LipexSil™ 2 nd generation lipids
prove their efficacy in the transfection of GFP and Luciferase mRNA into cells.
In a cooperation AldexChem Ltd. and Latvian LIOS file a FLPP grant application titled
“Application of catalytic hydrosilylation in the valorisation of renewables”.
studies).
First phase synthesis of LipexSil™ 2 nd generation lipids is completed which results
more than 30 new lipids.
AldexChem protects the LipexSil™ 2 nd generation lipids by filing a provisional patent
application.
2021
October
application.
studies are launched.
results further 50 lipids. AldexChem identifies a new lipid family and first phase
synthesis of LipexSil™ 2 nd generation lipids is initiated.
LipexSil™ is registered as a Hungarian national trademark (SZTNH), and
applications for international trademarks (WIPO) have been started.
Reaction scope investigation, and technological development of SilBoRed™ borane catalysts’ applications are launched.
SilBoRed™ is registered as a Hungarian national trademark (SZTNH), and applications for international trademarks (WIPO) have been started.
toxicity in the function of mRNA concentration.
Preliminary in vitro biological results of the selected LipexSil™ 2nd generation lipids prove their efficacy in the transfection of GFP and Luciferase mRNA into cells.
In a cooperation AldexChem Ltd. and Latvian LIOS file a FLPP grant
application titled “Application of catalytic hydrosilylation in the valorisation of renewables”.
LipexSil™ is registered as a Hungarian national trademark (SZTNH), and applications for international trademarks (WIPO) have been started.
studies).
First phase synthesis of LipexSil™ 2nd generation lipids is completed which results more than 30 new lipids.
AldexChem protects the LipexSil™ 2nd generation lipids by filing a provisional patent application.
.jpg)
.jpg)
